OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: To determine the benefits and harms of oral food or fluid restriction, or both, during labour.
Abstract Introduction: Pirtobrutinib is a highly selective, non-covalent (nc) Bruton tyrosine kinase inhibitor (BTKi) that has demonstrated safety and efficacy in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including pts previously treated with a cBTKi. While cBTKi have significantly improved progression-free survival (PFS) for untreated pts with CLL/SLL, there are no Phase 3 data assessing a ncBTKi specifically in the treatment-naïve setting, and significant improvements in overall survival (OS) are uncommon with monotherapy cBTKi. A recent head-to-head phase 3 trial (BRUIN CLL-314 presented at this meeting, ASH abstract 25-2587; NCT05254743) showed a favorable overall response rate (ORR) and a positive PFS trend with pirtobrutinib compared to the cBTKi ibrutinib in a subset of pts with treatment-naïve CLL. Here we present the first results from a randomized, open-label, global phase 3 trial specifically assessing the efficacy and safety of pirtobrutinib versus bendamustine plus rituximab (BR) in treatment-naïve pts with CLL/SLL (BRUIN CLL-313; NCT05023980). Methods: Pts with previously untreated CLL/SLL, without del(17p), were randomized 1:1 to receive pirtobrutinib monotherapy (200 mg QD) or 6 cycles of BR, stratified by IGHV mutation status (mutated vs unmutated) and Rai stage (low/intermediate vs high). Pts with known CLL/SLL CNS involvement, Richter transformation, or significant cardiovascular disease were excluded. Responses were evaluated using iwCLL 2018 criteria. The primary endpoint was PFS assessed by independent review committee (IRC), and a stratified log-rank test compared IRC-assessed PFS between pirtobrutinib and BR using a 2-sided alpha level of 0.05. OS was a key secondary endpoint, gated on IRC-assessed PFS, with a small alpha of 0.000001 spent at this interim OS analysis. Other secondary endpoints included investigator (INV)-assessed PFS and safety. Efficacy analyses were based on the intent-to-treat population. Pts assigned to BR were eligible to cross over to receive pirtobrutinib if they had IRC-confirmed disease progression (PD), met study eligibility requirements, and needed therapy per iwCLL criteria. The data cutoff was 11 July 2025. Results: 282 pts were randomized to receive either pirtobrutinib (n=141) or BR (n=141). At a median follow-up of 28.1 months, the primary endpoint of IRC-assessed PFS was significantly improved with pirtobrutinib compared with BR (HR: 0.199; 95% CI: 0.107, 0.367; p<0.0001). The 24-month PFS rate was 93.4% (95% CI: 87.6, 96.5) for pirtobrutinib and 70.7% (95% CI: 61.5, 78.1) for BR. IRC-assessed PFS benefit was consistently observed with pirtobrutinib among prespecified, clinically relevant patient subgroups, including patients with mutated IGHV (HR: 0.293, 95% CI: 0.094, 0.910), and unmutated IGHV (HR: 0.172, 95% CI: 0.083, 0.357). The PFS by INV was consistent (HR: 0.186; 95% CI: 0.093, 0.371; p<0.0001). The OS HR for pirtobrutinib versus BR was 0.257 (95% CI: 0.070, 0.934; p=0.0261), despite an effective crossover rate of 52.9% (18/34 pts with INV-assessed PD). The median treatment duration was 32.3 months for 140 pts receiving pirtobrutinib and 5.6 months for 132 pts receiving BR. The incidence of grade ≥3 TEAEs was 40.0% with pirtobrutinib and 67.4% with BR. Grade 5 TEAEs occurred in 1 pt receiving pirtobrutinib and 4 pts receiving BR, with none considered pirtobrutinib related and 1 (tumor lysis syndrome) considered BR related. Discontinuation of pirtobrutinib and BR due to TEAE occurred in 6 (4.3%) and 20 (15.2%) pts, respectively. Two pts (1.4%) receiving pirtobrutinib had a TEAE of atrial fibrillation/flutter, including only 1 of 20 pts aged ≥75 years. Conclusions: In BRUIN CLL-313, pirtobrutinib significantly improved IRC-assessed PFS versus BR for pts with treatment-naïve CLL/SLL with one of the largest treatment effects ever observed for a single-agent BTKi against this comparator. Pirtobrutinib was well tolerated, consistent with its known safety profile, with low rates of discontinuation and atrial fibrillation/flutter. While OS data remained immature, a notable trend favoring pirtobrutinib was observed, despite 52.9% of BR pts crossing over to receive pirtobrutinib after PD. Taken together, these data suggest that pirtobrutinib may be considered a potential new standard-of-care treatment for pts with untreated CLL/SLL, including older pts who may receive only one line of therapy.
Introduction: Cryotherapy, encompassing whole-body cryotherapy (WBC) and partial-body cryotherapy (PBC), has gained increasing attention in sports, medicine, rehabilitation, and wellness for its potential anti-inflammatory, analgesic, and recovery-enhancing effects. Originally developed in Japan in the late 1970s for the treatment of rheumatoid arthritis, WBC has since evolved into a multidisciplinary therapeutic modality with a wide range of clinical and non-clinical applications. Materials and Methods: A systematic literature search of PubMed and Embase from 2013–2025 was conducted using the terms “cryotherapy,” “whole-body cryotherapy,” and “cryostimulation.” Results: The evidence suggests that WBC elicits systemic anti-inflammatory effects through modulation of cytokines (e.g., decreased IL-1β, TNF-α, and hsCRP; increased IL-10), enhances antioxidant enzyme activity, and improves markers of oxidative stress. Clinical data further indicate beneficial outcomes in conditions such as rheumatic and osteoarticular diseases, fibromyalgia, multiple sclerosis, mood disorders, chronic pain, and obesity. WBC may also support athletic recovery by reducing muscle soreness and improving performance adaptation. Despite its broad therapeutic potential, contraindications, including cardiovascular, neurological, and cold-related disorders, must be observed. Reported adverse effects are generally mild and transient. Conclusions: Overall, cryotherapy appears to be a promising adjunctive modality, though further controlled studies are warranted to establish standardised treatment protocols and confirm long-term safety and efficacy.
Introduction and purpose: Systemic lupus erythematosus is a chronic, multifaceted autoimmune disorder. Throughout its course, it affects multiple organ systems, such as the skin, joints, kidneys, cardiovascular system, and central nervous system, among others. Less frequently observed clinical presentations include gastrointestinal involvement and hepatic symptoms. The objective of this review is to present and familiarise readers with these atypical manifestations, which are mostly not included in the diagnostic criteria for lupus, and which can pose a significant diagnostic challenge. Description of the state of knowledge: Gastrointestinal (GI) and hepatic symptoms among patients with lupus may be related to the disease itself, but can also result from the side effects of treatment, viral infections, or emerge as a consequence of the overlap of two diseases. The gastrointestinal tract may exhibit symptoms of the disease at practically any point along its course, from the oral cavity to the anus. The most common GI manifestations include conditions such as oral ulcers, dysphagia, lupus enteritis, protein-losing enteropathy, intestinal pseudo-obstruction, and pancreatitis. Rare, but clinically significant presentations of lupus involving the liver, which are important due to their chronic health consequences, include autoimmune hepatitis and lupus hepatitis. Conclusions: Patients with systemic lupus erythematosus who present with gastrointestinal or hepatic symptoms require prompt diagnosis, as these conditions, if not properly managed, contribute to increased mortality. It is also possible for these manifestations to appear as the initial signs of SLE. Therefore, familiarity with their characteristics is crucial to avoid delays in diagnosis and in the implementation of appropriate treatment.
Tumor-associated macrophages (TAMs) have often been classified as either inflammatory M1 or immunosuppressive M2 macrophages. This simplified model had predominantly been informed by in vitro polarization assays and in situ analyses relying on a limited set of cellular markers. The advent of single-cell transcriptomics enabled a more holistic and unbiased investigation of TAMs. We investigated cell subpopulations that are associated with beneficial outcomes in NSCLC patients (n = 219) receiving a weekly dose of 10 mg/kg anti-PD-L1 within the NCT02576574 trial. To leverage the power of single cell technologies, we used a bioinformatical method called Scissor, which identifies distinct cell subsets from single cell data integrated with bulk expression and clinical outcome data. Indication-matched published single cell expression data from three independent studies were used to this end. In all single cell datasets tested, we identified a distinct subset of TAMs that was associated with improved progression-free survival in patients treated with anti-PD-L1. Interestingly, this cell population was a subset of a larger cell cluster that had been previously classified as M2 macrophages due to their expression of CD163. We confirmed our findings using an independent published dataset consisting of 135 NSCLC patients treated with immune checkpoint inhibitors and bulk RNA-seq data with similar results. When further characterizing the TAM subset within the single cell expression data, we found these cells expressed TREM2, C1Qs, FOLR2 and APOE consistent with lipid-associated macrophages. This subset was distinct from TAM subpopulations expressing marker genes such as SPP1 and VCAN (angiogenic TAMs). Notably, these TAMs produced chemokines CXCL9, a gene that had been strongly associated with clinical response to immunotherapy, as well as CCL18, which was shown to promote cancer invasiveness. To investigate the spatial distribution of CD163+ TAMs in general we turned to the IMMUcan dataset. IMMUcan is a public-private EU funded consortium profiling the human tumor microenvironment (TME) in 2, 500+ patients and currently hosting one of the largest cancer-related imaging mass cytometry (IMC) datasets to date. Within the advanced NSCLC cohort we found that CD163+ TAMs were frequently in direct contact with tumor cells. Finally, patients with high CD163+ TAMs in the TME were distinct from patients with high CD8+ T cell infiltration. These data suggest that macrophage subpopulations that were previously considered to have an immunosuppressive role can be associated with clinical benefit to immunotherapy. Targeting these TAMs as part of immune checkpoint inhibitor blockade may be worthwhile given their ambiguous role. Henoch S. Hong, Marzena Mura, Jing Yang, Aslihan Gerhold-Ay, Thomas Mrowiec, Daniel Schulz, Bernd Bodenmiller, Robin Liechti, Marie Morfouace, Parantu Shah, Alex Rolfe. Tumor-associated macrophages and clinical outcomes to immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1177.